TriangleTrastuzumab Deruxtecan (NCT06750484)
Trastuzumab Deruxtecan trial for Breast Cancer Metastatic (NCT06750484). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable or metastatic breast cancer that has always tested HER2-IHC 0. Prior treatment requirements depend on hormone-receptor status; previous HER2-targeted treatment excludes participation.
The idea: trastuzumab deruxtecan carries a DNA-disrupting drug on a HER2-targeting antibody. Researchers test its activity in this specific group, including tumors with no detectable staining. Everyone receives intravenous treatment every three weeks; tumor tissue is required for testing.
This phase 2 study plans 40 patients. Adriana Kahn leads at Yale in New Haven; three US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.